Cargando…
No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids
Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neut...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175720/ https://www.ncbi.nlm.nih.gov/pubmed/34123387 http://dx.doi.org/10.1002/rcr2.799 |
_version_ | 1783703103500976128 |
---|---|
author | Kanai, Osamu Nakatani, Koichi Fujita, Kohei Okamura, Misato Mio, Tadashi |
author_facet | Kanai, Osamu Nakatani, Koichi Fujita, Kohei Okamura, Misato Mio, Tadashi |
author_sort | Kanai, Osamu |
collection | PubMed |
description | Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neutropenia and thrombocytopenia. The bone marrow biopsy and serum immunological tests indicated no evidence of bone marrow failure and suggested autoimmune mature blood cell destruction. After initiating treatment with prednisolone 50 mg orally and filgrastim 75 μg subcutaneously once daily, neutropenia and thrombocytopenia recovered within four and nine days, respectively. The filgrastim was discontinued four days later, and the corticosteroid was discontinued three months later; there has been no haemocytopenia recurrence since then. The patient has remained untreated for more than two years without progression of lung cancer. In conclusion, corticosteroids should be considered for the treatment of autoimmune haemocytopenia if refractory bone marrow dysplasia can be ruled out. |
format | Online Article Text |
id | pubmed-8175720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-81757202021-06-11 No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids Kanai, Osamu Nakatani, Koichi Fujita, Kohei Okamura, Misato Mio, Tadashi Respirol Case Rep Case Reports Unlike cytotoxicity, haematological toxicity is a rare immune‐related adverse event that is occasionally irreversible and refractory. A 67‐year‐old man was diagnosed with advanced lung squamous cell carcinoma. After 41 cycles of nivolumab as third‐line chemotherapy, the patient developed severe neutropenia and thrombocytopenia. The bone marrow biopsy and serum immunological tests indicated no evidence of bone marrow failure and suggested autoimmune mature blood cell destruction. After initiating treatment with prednisolone 50 mg orally and filgrastim 75 μg subcutaneously once daily, neutropenia and thrombocytopenia recovered within four and nine days, respectively. The filgrastim was discontinued four days later, and the corticosteroid was discontinued three months later; there has been no haemocytopenia recurrence since then. The patient has remained untreated for more than two years without progression of lung cancer. In conclusion, corticosteroids should be considered for the treatment of autoimmune haemocytopenia if refractory bone marrow dysplasia can be ruled out. John Wiley & Sons, Ltd 2021-06-03 /pmc/articles/PMC8175720/ /pubmed/34123387 http://dx.doi.org/10.1002/rcr2.799 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Case Reports Kanai, Osamu Nakatani, Koichi Fujita, Kohei Okamura, Misato Mio, Tadashi No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids |
title | No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids |
title_full | No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids |
title_fullStr | No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids |
title_full_unstemmed | No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids |
title_short | No need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids |
title_sort | no need to hesitate: immune‐related neutropenia and thrombocytopenia that improved by corticosteroids |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175720/ https://www.ncbi.nlm.nih.gov/pubmed/34123387 http://dx.doi.org/10.1002/rcr2.799 |
work_keys_str_mv | AT kanaiosamu noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids AT nakatanikoichi noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids AT fujitakohei noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids AT okamuramisato noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids AT miotadashi noneedtohesitateimmunerelatedneutropeniaandthrombocytopeniathatimprovedbycorticosteroids |